← brief for 2026-09-16 · Slowing decline

Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This meta-analysis pooled results from earlier studies to ask whether SGLT2 inhibitors slow kidney disease and help people live longer. SGLT2 inhibitors are a class of drugs first made for diabetes, such as empagliflozin and dapagliflozin. A meta-analysis is the strongest kind of evidence. The number of studies, the number of people, and the size of the benefit were not in the text we had, so check the full paper for those figures.

Who did this work

Sharma A · Sharma B · Vamaraju DS · Ajay AK

Source

Article · PubMed, the drug frontier · 2026 Aug 31
https://pubmed.ncbi.nlm.nih.gov/42741446/